

# Humanigen, Inc.

09:45 16 Jul 2020

## Humanigen bolsters partnership with Catalent to produce lenzilumab for coronavirus trials

Humanigen Inc (OTC:HGEN) and Catalent Biologics have expanded their partnership, which sees Catalent provide development, manufacturing and commercialization services for Humanigen's drug lenzilumab, the companies announced Thursday.

The Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical coronavirus (COVID-19) related pneumonia, the majority of whom showed rapid recovery and hospital discharge, the company said. A Phase 3 study is currently underway evaluating hospitalized coronavirus patients.

"Based on lenzilumab's promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab," Humanigen CEO Cameron Durrant said in a statement. "If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics' deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most."

### READ: Humanigen strengthens leadership team with three new executive appointments

Catalent Biologics has delivered early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin. Under the expanded partnership, Catalent will also provide clinical supply support for Humanigen's Phase 3 potential registration study of COVID-19 from its Philadelphia facility.

The company's OneBio Suite is an integrated solution for the development, manufacturing and supply of biologic drugs. The suite of offerings is designed to accelerate timelines, reduce risk and simplify development.

"Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials," Catalent CCO Karen Flynn said. "The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to Covid-19 patients as soon as possible following receipt of regulatory approvals."

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

### 1 Year Share Price Graph



### Share Information

**Code:** HGEN  
**Listing:** OTCQB  
**Sector:** Pharma & Biotech  
**Website:** [www.humanigen.com](http://www.humanigen.com)

### Company Synopsis:

Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).